# AdvanTIG-302 (NCT04746924)

> A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

No report yet. It can be ordered.

- Drugs tested: ociperlimab plus tislelizumab
- Indication: untreated PD-L1-selected locally advanced, unresectable or metastatic NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04746924
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: BeiGene
- Conditions: Non-small Cell Lung Cancer; NSCLC
- Interventions: Tislelizumab; Ociperlimab; Pembrolizumab; Placebo
- Enrollment: 669
- Primary outcome: Overall Survival (OS) in Arms A and B
- Primary outcome: Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)
- Primary outcome: Safety Run-In Substudy: Serum Concentration of Ociperlimab

## Indexed commentary on AdvanTIG-302 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=advantig-302-nct04746924